Next-Generation Bispecific Nanobody Targeting CD3 Complex and GUCY2C for Advanced Colon Cancer Immunotherapy
VHH-P347 is a humanized bispecific nanobody designed to engage both the CD3 Complex (T Cell Receptor Complex) and guanylate cyclase 2C (GUCY2C), key players in cellular immunity and oncogenic signaling, respectively. Currently in the Biological Testing phase, VHH-P347 holds significant potential for the treatment of colon cancer. By targeting CD3 Complex (T Cell Receptor Complex) on T cells and GUCY2C on malignant cells, this innovative construct aims to harness the immune system to achieve targeted cytotoxicity. VHH-P347 exemplifies a new generation of nanobody-based immunotherapeutics with promise for addressing unmet needs in colon cancer intervention.
| Candidate | VHH-P347 |
| Target | CD3 Complex (T Cell Receptor Complex) guanylate cyclase 2C (GUCY2C) |
| Modality | humanized bispecific VHH |
| Indication | Colon Cancer |
Licensing Opportunity
VHH-P347 is available for out-licensing and collaborative development opportunities. Partners interested in advancing this innovative bispecific nanobody toward clinical application in colon cancer are welcome to inquire.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P347 |
Modality
VHH-P347 is a bispecific antibody fusion consisting of two engineered polypeptide chains. The construct features a humanized single-chain variable fragment targeting CD3, paired with a constant heavy chain (CH2) and Fc region with knob mutations, as well as a humanized single-domain nanobody targeting GUCY2C, fused to CH2 and Fc carrying hole mutations and additional Fc modifications to modulate immune functions. Expressed in Expi293 cells, this nanobody-based modality benefits from the inherent advantages of single-domain antibodies, such as small size, high stability, and enhanced tissue penetration. These attributes are especially valuable for treating solid tumors like colon cancer, enabling improved tumor targeting and potentially overcoming physical and immunological barriers encountered by conventional antibodies.
Target
CD3 Complex is a multiprotein assembly located on T cells, crucial for T cell activation and immune response modulation. By engaging the CD3 Complex, VHH-P347 efficiently recruits T cells to tumor sites. GUCY2C, a membrane-associated enzyme predominantly expressed in intestinal epithelial cells, is overexpressed in many colon cancer cells but remains limited in healthy tissues, making it an appealing tumor antigen. Simultaneous targeting of CD3 Complex and GUCY2C provides strategic advantages for selective tumor cell eradication, minimizing off-target effects. The specific interaction with the CD3 Complex ensures potent immunological synapse formation, while GUCY2C targeting ensures selectivity within the tumor microenvironment, positioning VHH-P347 as a highly differentiated therapeutic asset in colon cancer immunotherapy.
Mechanism of Action
VHH-P347 functions as a T-cell engager by simultaneously binding CD3 Complex on T cells and GUCY2C on tumor cells, thereby facilitating the formation of an immunological synapse and targeted cytotoxicity. The anti-CD3 arm recruits and activates T cells independent of endogenous antigen recognition, while the anti-GUCY2C arm provides tumor specificity by directing immune activity toward cancer cells. This dual engagement modulates intracellular signal transduction pathways, promoting immune-mediated apoptosis of GUCY2C-expressing colon cancer cells. The nanobody platform supports further modular development, including antibody-drug conjugates and bispecific T-cell engagers tailored for various cancer indications, underscoring the versatile therapeutic applications of this approach.
Colon Cancer
Colon cancer is one of the most prevalent malignancies worldwide, with significant morbidity and mortality. The disease is characterized by malignant transformation of the large intestine's mucosal lining, often progressing insidiously until advanced stages. Standard treatments include surgical resection, chemotherapy, radiation therapy, and the advent of biologics and targeted agents. Despite therapeutic advances, the prognosis for advanced or metastatic colon cancer remains poor due to drug resistance, relapse, and limited efficacy of current immunotherapies. There is a critical need for more effective, selective, and durable treatment options. VHH-P347, through its dual targeting strategy, has the potential to address several clinical challenges by redirecting immune effector mechanisms specifically to tumor cells, improving therapeutic outcomes and expanding the treatment landscape for colon cancer.